This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...

Biotech stocks may be primed for a long-term bull run. Learn why IBB, XBI, and macro trends like rate cuts make biotech an ...

Bluejay Therapeutics, a drug developer focused on serious viral and liver diseases, is considering a US initial public offering, according to people familiar with the matter.

March 7, 2025 (Investorideas.com Newswire) Investorideas.com, a recognized top 100 investment site for stock news announces ...

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more ...

Many of these trends would seem not to make sense on the surface ... Last year saw a continuation of a suppressed number of biotech IPOs, but a robust number of secondary offerings by companies ...

The likes of BioAge Labs Inc and MBX Biosciences Inc will seek to buck that trend with industry bankers ... “Investors in biotech IPOs are here and ready to put money to work.” ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

Paramesu Biotechs IPO aims to raise ₹600 crore for expansion and debt repayment, showcasing strong financial performance and ...

Hinge Health, Inc. targets a $326B market with innovative musculoskeletal care solutions. Click here to find out more about the upcoming HNGE stock IPO.

Oncolytics Biotech Inc. (ONCY ... as indicated by its RSI reading of 27.83. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.